Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Astellas Pharma
Astellas Pharma
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Regulatory
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Manufacturing
Astella invests $3.5m in antibody drug facility
Drug producer Astella is set to submit a planning application to build a new facility in Tralee (County Kerry), Ireland, to expand its capacity to develop antibody drugs
Ingredients
Therapeutic: zolbetuximab for gastric cancer
Stomach cancer is the fifth most commonly diagnosed form of cancer, with risk factors including age, smoking, H. pylori infection and gastro-oesophageal reflux disease
Finance
Astellas acquires mitochondrial specialist for $15m
Astellas Pharma has acquired Nanna Therapeutics, a UK biotech focused on addressing age-related diseases with high unmet medical need including mitochondria-related diseases
Research & Development
Astellas invests $13m in cell and gene therapy innovation incubators
Japanese Astellas’ nearly $13m will make it a Founding Sponsor of LabCentral's new incubator with a core lab space for process development studies and a non-GMP pilot plant
Pharmaceutical
Astellas names Rodrigo Fernandez as Executive Director, International Business
Fernandez to lead Astellas' business in Latin America outside Brazil
Subscribe now